CA2419115C - Microparticles, and method and apparatus for forming same - Google Patents
Microparticles, and method and apparatus for forming same Download PDFInfo
- Publication number
- CA2419115C CA2419115C CA2419115A CA2419115A CA2419115C CA 2419115 C CA2419115 C CA 2419115C CA 2419115 A CA2419115 A CA 2419115A CA 2419115 A CA2419115 A CA 2419115A CA 2419115 C CA2419115 C CA 2419115C
- Authority
- CA
- Canada
- Prior art keywords
- particles
- stream
- nozzle
- liquid
- diameter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 101
- 239000011859 microparticle Substances 0.000 title description 8
- 239000002245 particle Substances 0.000 claims abstract description 144
- 239000007788 liquid Substances 0.000 claims abstract description 95
- 239000002105 nanoparticle Substances 0.000 claims abstract description 27
- 230000008569 process Effects 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 35
- 238000004519 manufacturing process Methods 0.000 claims description 31
- 238000005086 pumping Methods 0.000 claims description 10
- 239000011344 liquid material Substances 0.000 claims description 4
- 239000010420 shell particle Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229940124447 delivery agent Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 239000011257 shell material Substances 0.000 description 54
- 239000004005 microsphere Substances 0.000 description 53
- -1 poly(orthoesters) Polymers 0.000 description 40
- 229920000642 polymer Polymers 0.000 description 40
- 239000000463 material Substances 0.000 description 39
- 238000009826 distribution Methods 0.000 description 35
- 229940079593 drug Drugs 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 26
- 239000002077 nanosphere Substances 0.000 description 23
- 239000011162 core material Substances 0.000 description 22
- 238000012377 drug delivery Methods 0.000 description 21
- 239000000243 solution Substances 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 15
- 238000013270 controlled release Methods 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 13
- 239000012798 spherical particle Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000005284 excitation Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000012071 phase Substances 0.000 description 9
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 9
- 238000005538 encapsulation Methods 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 229940043267 rhodamine b Drugs 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 102100038124 Plasminogen Human genes 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 229920002988 biodegradable polymer Polymers 0.000 description 6
- 239000004621 biodegradable polymer Substances 0.000 description 6
- 230000009977 dual effect Effects 0.000 description 6
- 238000007590 electrostatic spraying Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000003980 solgel method Methods 0.000 description 6
- 238000005507 spraying Methods 0.000 description 6
- 239000011324 bead Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000007787 electrohydrodynamic spraying Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229920002732 Polyanhydride Polymers 0.000 description 3
- 239000004965 Silica aerogel Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 108010067396 dornase alfa Proteins 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002078 nanoshell Substances 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229960001652 norethindrone acetate Drugs 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 1
- NUBQKPWHXMGDLP-UHFFFAOYSA-N 1-[4-benzyl-2-hydroxy-5-[(2-hydroxy-2,3-dihydro-1h-inden-1-yl)amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;sulfuric acid Chemical compound OS(O)(=O)=O.C1CN(CC(O)CC(CC=2C=CC=CC=2)C(=O)NC2C3=CC=CC=C3CC2O)C(C(=O)NC(C)(C)C)CN1CC1=CC=CN=C1 NUBQKPWHXMGDLP-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- XRHVZWWRFMCBAZ-UHFFFAOYSA-L Endothal-disodium Chemical compound [Na+].[Na+].C1CC2C(C([O-])=O)C(C(=O)[O-])C1O2 XRHVZWWRFMCBAZ-UHFFFAOYSA-L 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 229940124914 Havrix Drugs 0.000 description 1
- 101000863721 Homo sapiens Deoxyribonuclease-1 Proteins 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960004342 cetirizine hydrochloride Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 238000010961 commercial manufacture process Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000011246 composite particle Substances 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 229960000533 dornase alfa Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229940085363 evista Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960002107 fluvoxamine maleate Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000055805 human DNASE1 Human genes 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 description 1
- OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 description 1
- AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
- 229960002102 imipramine hydrochloride Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960004243 indinavir sulfate Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003358 interferon alfacon-1 Drugs 0.000 description 1
- 108010010648 interferon alfacon-1 Proteins 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- 210000003126 m-cell Anatomy 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 229960005040 miconazole nitrate Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 229940000973 monistat Drugs 0.000 description 1
- 229910000096 monohydride Inorganic materials 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- 229960002194 oseltamivir phosphate Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229940045258 pancrelipase Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical class NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 229940107568 pulmozyme Drugs 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
- 229940036139 zyrtec Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/04—Making microcapsules or microballoons by physical processes, e.g. drying, spraying
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Manufacturing & Machinery (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicinal Preparation (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22552500P | 2000-08-15 | 2000-08-15 | |
| US22562000P | 2000-08-15 | 2000-08-15 | |
| US60/225,620 | 2000-08-15 | ||
| US60/225,525 | 2000-08-15 | ||
| PCT/US2001/025674 WO2002013786A2 (en) | 2000-08-15 | 2001-08-15 | Method of forming microparticles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2419115A1 CA2419115A1 (en) | 2002-02-21 |
| CA2419115C true CA2419115C (en) | 2011-03-08 |
Family
ID=26919678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2419115A Expired - Lifetime CA2419115C (en) | 2000-08-15 | 2001-08-15 | Microparticles, and method and apparatus for forming same |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6669961B2 (enExample) |
| EP (1) | EP1355630B1 (enExample) |
| JP (1) | JP2004505761A (enExample) |
| KR (2) | KR100902625B1 (enExample) |
| AT (1) | ATE449596T1 (enExample) |
| AU (1) | AU2001284982A1 (enExample) |
| CA (1) | CA2419115C (enExample) |
| DE (1) | DE60140625D1 (enExample) |
| WO (1) | WO2002013786A2 (enExample) |
Families Citing this family (253)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101460240B1 (ko) * | 2008-06-13 | 2014-11-21 | 삼성전자주식회사 | 메모리 기반 저장 장치 및 그것의 블록 관리 기법 |
| US7615373B2 (en) | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
| US20020081732A1 (en) | 2000-10-18 | 2002-06-27 | Bowlin Gary L. | Electroprocessing in drug delivery and cell encapsulation |
| CA2419115C (en) * | 2000-08-15 | 2011-03-08 | Board Of Trustees Of The University Of Illinois | Microparticles, and method and apparatus for forming same |
| US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
| US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
| US7193084B2 (en) | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
| US9700866B2 (en) * | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
| US6951656B2 (en) | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US7037528B2 (en) | 2000-12-22 | 2006-05-02 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US6884436B2 (en) | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
| US6977085B2 (en) | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
| US6518330B2 (en) * | 2001-02-13 | 2003-02-11 | Board Of Trustees Of University Of Illinois | Multifunctional autonomically healing composite material |
| US6610223B2 (en) | 2001-03-30 | 2003-08-26 | Picoliter Inc. | Focused acoustic energy in the generation of solid particles |
| WO2003000741A1 (fr) * | 2001-06-22 | 2003-01-03 | Sekisui Chemical Co., Ltd. | Procede de preparation de particules de resine, particules de resine et appareil permettant de preparer lesdites particules |
| WO2003002243A2 (en) | 2001-06-27 | 2003-01-09 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
| US20040241094A1 (en) * | 2001-09-13 | 2004-12-02 | Hesson Chung | Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof |
| US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
| CN1558755A (zh) * | 2001-09-26 | 2004-12-29 | ���ع��ʹ�˾ | 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒 |
| US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
| US7462366B2 (en) | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
| US7094369B2 (en) | 2002-03-29 | 2006-08-22 | Scimed Life Systems, Inc. | Processes for manufacturing polymeric microspheres |
| US7131997B2 (en) | 2002-03-29 | 2006-11-07 | Scimed Life Systems, Inc. | Tissue treatment |
| US7053134B2 (en) | 2002-04-04 | 2006-05-30 | Scimed Life Systems, Inc. | Forming a chemically cross-linked particle of a desired shape and diameter |
| US7001920B2 (en) * | 2002-06-10 | 2006-02-21 | Wyeth | Formate salt of O-desmethyl-venlafaxine |
| US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| US7449236B2 (en) | 2002-08-09 | 2008-11-11 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
| US7842377B2 (en) * | 2003-08-08 | 2010-11-30 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
| US8012454B2 (en) | 2002-08-30 | 2011-09-06 | Boston Scientific Scimed, Inc. | Embolization |
| US7588825B2 (en) | 2002-10-23 | 2009-09-15 | Boston Scientific Scimed, Inc. | Embolic compositions |
| US7883490B2 (en) | 2002-10-23 | 2011-02-08 | Boston Scientific Scimed, Inc. | Mixing and delivery of therapeutic compositions |
| US7623908B2 (en) | 2003-01-24 | 2009-11-24 | The Board Of Trustees Of The University Of Illinois | Nonlinear interferometric vibrational imaging |
| US20080199701A1 (en) * | 2003-02-25 | 2008-08-21 | Kuehnle Manfred R | Encapsulated nanoparticles for the absorption of electromagnetic energy |
| CA2557348A1 (en) * | 2003-02-25 | 2004-09-10 | Xmx Corporation | Encapsulated nanoparticles for the absorption of electromagnetic energy |
| JP2006524738A (ja) * | 2003-02-25 | 2006-11-02 | マンフレッド・アール・クーンル | 紫外線帯域の電磁エネルギー吸収用のカプセル化されたナノ粒子 |
| US7511079B2 (en) * | 2003-03-24 | 2009-03-31 | Baxter International Inc. | Methods and apparatuses for the comminution and stabilization of small particles |
| JP4305729B2 (ja) * | 2003-03-28 | 2009-07-29 | セイコーエプソン株式会社 | 液体吐出装置及びマイクロカプセルの製造方法 |
| CA2784762A1 (en) | 2003-04-10 | 2004-10-28 | President And Fellows Of Harvard College | Formation and control of fluidic species |
| US7285306B1 (en) * | 2003-04-18 | 2007-10-23 | United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Process for self-repair of insulation material |
| CA2526362C (en) | 2003-05-20 | 2012-10-09 | James F. Collins | Ophthalmic drug delivery system |
| US8012136B2 (en) | 2003-05-20 | 2011-09-06 | Optimyst Systems, Inc. | Ophthalmic fluid delivery device and method of operation |
| US7217410B2 (en) * | 2003-06-17 | 2007-05-15 | The Board Of Trustees Of The Universtiy Of Illinois | Surface modified protein microparticles |
| US7198777B2 (en) * | 2003-06-17 | 2007-04-03 | The Board Of Trustees Of The University Of Illinois | Optical contrast agents for optically modifying incident radiation |
| US8021593B2 (en) * | 2003-07-31 | 2011-09-20 | Sijtechnology, Inc. | Method of producing a three-dimensional structure and fine three-dimensional structure |
| CN1842368B (zh) | 2003-08-27 | 2014-05-28 | 哈佛大学 | 流体物种的电子控制 |
| US7976823B2 (en) | 2003-08-29 | 2011-07-12 | Boston Scientific Scimed, Inc. | Ferromagnetic particles and methods |
| US20070158450A1 (en) * | 2003-09-09 | 2007-07-12 | John Scattergood | Systems and methods for producing fine particles |
| US7901770B2 (en) | 2003-11-04 | 2011-03-08 | Boston Scientific Scimed, Inc. | Embolic compositions |
| US20050175836A1 (en) * | 2003-11-12 | 2005-08-11 | Xmx Corporation | Physical color new concepts for color pigments |
| US20070141342A1 (en) * | 2003-11-12 | 2007-06-21 | Kuehnle Manfred R | Physical color new concepts for color pigments |
| US7309500B2 (en) | 2003-12-04 | 2007-12-18 | The Board Of Trustees Of The University Of Illinois | Microparticles |
| US9040090B2 (en) | 2003-12-19 | 2015-05-26 | The University Of North Carolina At Chapel Hill | Isolated and fixed micro and nano structures and methods thereof |
| CA2549341C (en) | 2003-12-19 | 2014-06-10 | The University Of North Carolina At Chapel Hill | Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography |
| US7610074B2 (en) * | 2004-01-08 | 2009-10-27 | The Board Of Trustees Of The University Of Illinois | Multi-functional plasmon-resonant contrast agents for optical coherence tomography |
| WO2005077337A2 (en) * | 2004-02-05 | 2005-08-25 | Baxter International Inc. | Dispersions prepared by use of self-stabilizing agents |
| CN100431684C (zh) | 2004-02-23 | 2008-11-12 | 视觉股份公司 | 离子交联的多糖微球体的生产方法 |
| US7736671B2 (en) | 2004-03-02 | 2010-06-15 | Boston Scientific Scimed, Inc. | Embolization |
| US8173176B2 (en) | 2004-03-30 | 2012-05-08 | Boston Scientific Scimed, Inc. | Embolization |
| US7566747B2 (en) * | 2004-05-07 | 2009-07-28 | The Board Of Trustees Of The University Of Illinois | Wax particles for protection of activators, and multifunctional autonomically healing composite materials |
| US7311861B2 (en) * | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
| EP3326617A1 (en) | 2004-06-12 | 2018-05-30 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
| JP4762517B2 (ja) * | 2004-09-09 | 2011-08-31 | 株式会社オプトニクス精密 | プリンター用トナーの製造方法 |
| US8241651B2 (en) | 2004-11-10 | 2012-08-14 | The Regents Of The University Of Michigan | Multiphasic biofunctional nano-components and methods for use thereof |
| US8043480B2 (en) | 2004-11-10 | 2011-10-25 | The Regents Of The University Of Michigan | Methods for forming biodegradable nanocomponents with controlled shapes and sizes via electrified jetting |
| JP4690418B2 (ja) * | 2004-11-10 | 2011-06-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 多相ナノ粒子 |
| US7947772B2 (en) | 2004-11-10 | 2011-05-24 | The Regents Of The University Of Michigan | Multiphasic nano-components comprising colorants |
| US8187708B2 (en) | 2004-11-10 | 2012-05-29 | The Regents Of The University Of Michigan | Microphasic micro-components and methods for controlling morphology via electrified jetting |
| US7748343B2 (en) | 2004-11-22 | 2010-07-06 | The Board Of Trustees Of The University Of Illinois | Electrohydrodynamic spraying system |
| US20060140843A1 (en) * | 2004-12-23 | 2006-06-29 | In-Kyung Sung | Macroporous structures for heterogeneous catalyst support |
| US20060147536A1 (en) * | 2004-12-30 | 2006-07-06 | Fiore Robert A | Method for removing fluids containing dissolved or suspended carbohydrates, lipids, metals, salts, and/or toxins from biological systems |
| ES2257968B1 (es) * | 2005-01-28 | 2007-07-01 | Universidad De Sevilla | Procedimiento y dispositivo para la obtencion de particulas de tamaño micro y nanometrico. |
| WO2006086654A2 (en) * | 2005-02-11 | 2006-08-17 | Battelle Memorial Institute | Nanoformulations |
| US20090104269A1 (en) * | 2005-02-11 | 2009-04-23 | Brian Graham | Nanoformulations |
| US7586618B2 (en) * | 2005-02-28 | 2009-09-08 | The Board Of Trustees Of The University Of Illinois | Distinguishing non-resonant four-wave-mixing noise in coherent stokes and anti-stokes Raman scattering |
| US7858183B2 (en) | 2005-03-02 | 2010-12-28 | Boston Scientific Scimed, Inc. | Particles |
| US7727555B2 (en) * | 2005-03-02 | 2010-06-01 | Boston Scientific Scimed, Inc. | Particles |
| US7725169B2 (en) * | 2005-04-15 | 2010-05-25 | The Board Of Trustees Of The University Of Illinois | Contrast enhanced spectroscopic optical coherence tomography |
| US7963287B2 (en) | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
| US7612152B2 (en) * | 2005-05-06 | 2009-11-03 | The Board Of Trustees Of The University Of Illinois | Self-healing polymers |
| US8043323B2 (en) * | 2006-10-18 | 2011-10-25 | Inspiremd Ltd. | In vivo filter assembly |
| CA2843097C (en) | 2005-05-24 | 2015-10-27 | Inspire M.D Ltd. | Stent apparatuses for treatment via body lumens and methods of use |
| US8961586B2 (en) | 2005-05-24 | 2015-02-24 | Inspiremd Ltd. | Bifurcated stent assemblies |
| MX2007015183A (es) * | 2005-06-14 | 2008-02-19 | Baxter Int | Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco. |
| US20060280787A1 (en) * | 2005-06-14 | 2006-12-14 | Baxter International Inc. | Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof |
| US9463426B2 (en) * | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
| JP4854240B2 (ja) * | 2005-09-09 | 2012-01-18 | 株式会社オプトニクス精密 | 加圧振動及び噴射造粒による超微粒子 |
| US20070059370A1 (en) * | 2005-09-15 | 2007-03-15 | Industrial Technology Research Institute | Method and apparatus for fabricating nanoparticles |
| US20090099031A1 (en) * | 2005-09-27 | 2009-04-16 | Stemmer Willem P | Genetic package and uses thereof |
| CA2622441A1 (en) * | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| US7709544B2 (en) * | 2005-10-25 | 2010-05-04 | Massachusetts Institute Of Technology | Microstructure synthesis by flow lithography and polymerization |
| EP1954245A2 (en) * | 2005-11-15 | 2008-08-13 | Baxter International Inc. | Compositions of lipoxygenase inhibitors |
| CN1785153B (zh) * | 2005-12-06 | 2010-04-21 | 青岛大学 | 纳米级材料制备装置及纳米抗氧化活性多肽药物的制备方法 |
| CN101370479A (zh) * | 2005-12-16 | 2009-02-18 | 堪萨斯州立大学 | 用于递送治疗剂的纳米团簇 |
| US7993749B2 (en) * | 2005-12-16 | 2011-08-09 | University Of Kansas | Nanoparticles comprising a nanoparticle template and a polymer shell having an amide side chain, and method of making thereof |
| JP4823675B2 (ja) * | 2005-12-16 | 2011-11-24 | 花王株式会社 | ハイドロゲル粒子の製造方法、並びに、それによって製造されるハイドロゲル粒子及びそれを用いた分散体 |
| US8101197B2 (en) | 2005-12-19 | 2012-01-24 | Stryker Corporation | Forming coils |
| US7501179B2 (en) | 2005-12-21 | 2009-03-10 | Boston Scientific Scimed, Inc. | Block copolymer particles |
| US7947368B2 (en) | 2005-12-21 | 2011-05-24 | Boston Scientific Scimed, Inc. | Block copolymer particles |
| JP5738516B2 (ja) | 2005-12-30 | 2015-06-24 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | 心機能改善のためのニューレグリンの徐放 |
| WO2007082153A2 (en) | 2006-01-05 | 2007-07-19 | The Board Of Trustees Of The University Of Illinois | Self-healing coating system |
| US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
| WO2007090147A2 (en) | 2006-01-31 | 2007-08-09 | The Board Of Trustees Of The University Of Illinois | Method and apparatus for measurement of optical properties in tissue |
| US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
| US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
| US7569625B2 (en) * | 2006-06-02 | 2009-08-04 | The Board Of Trustees Of The University Of Illinois | Self-healing elastomer system |
| US8465775B2 (en) | 2006-07-27 | 2013-06-18 | The University Of North Carolina At Chapel Hill | Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells |
| EP2054537A2 (en) * | 2006-08-02 | 2009-05-06 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
| US8057534B2 (en) | 2006-09-15 | 2011-11-15 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
| EP2399616A1 (en) * | 2006-09-15 | 2011-12-28 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis with biostable inorganic layers |
| CA2663303A1 (en) * | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Endoprosthesis with adjustable surface features |
| WO2008034013A2 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Medical devices and methods of making the same |
| US8808726B2 (en) | 2006-09-15 | 2014-08-19 | Boston Scientific Scimed. Inc. | Bioerodible endoprostheses and methods of making the same |
| US8002821B2 (en) | 2006-09-18 | 2011-08-23 | Boston Scientific Scimed, Inc. | Bioerodible metallic ENDOPROSTHESES |
| US20080075785A1 (en) * | 2006-09-22 | 2008-03-27 | San-Laung Chow | Controlled release hydrogel formulation |
| US20110165236A1 (en) * | 2006-09-22 | 2011-07-07 | Biokey, Inc. | Controlled release hydrogel formulation |
| WO2008047369A2 (en) | 2006-10-18 | 2008-04-24 | Inspiremd Ltd. | Knitted stent jackets |
| US20100324664A1 (en) * | 2006-10-18 | 2010-12-23 | Asher Holzer | Bifurcated Stent Assemblies |
| US20080097577A1 (en) * | 2006-10-20 | 2008-04-24 | Boston Scientific Scimed, Inc. | Medical device hydrogen surface treatment by electrochemical reduction |
| JP5640196B2 (ja) * | 2006-11-02 | 2014-12-17 | 国立大学法人名古屋大学 | 微小カプセルの製造方法 |
| EP1958622A1 (en) * | 2006-11-07 | 2008-08-20 | Royal College of Surgeons in Ireland | Method of producing microcapsules |
| CN101578078B (zh) | 2006-11-22 | 2013-01-02 | 印斯拜尔Md有限公司 | 优化的支架套 |
| WO2008080047A2 (en) * | 2006-12-23 | 2008-07-03 | Baxter International Inc. | Magnetic separation of fine particles from compositions |
| ES2356274T3 (es) | 2006-12-28 | 2011-04-06 | Boston Scientific Limited | Endoprótesis biodegradables y procedimientos de fabricación de las mismas. |
| US20080182019A1 (en) * | 2007-01-30 | 2008-07-31 | Robert Retter | Hollow Microsphere Particle Generator |
| US20080182056A1 (en) * | 2007-01-30 | 2008-07-31 | Eric Bakker | Hollow Microsphere Particles |
| US8222988B2 (en) * | 2007-04-09 | 2012-07-17 | The Board Of Trustees Of The University Of Illinois | Porous device for optical and electronic applications and method of fabricating the porous device |
| US7872563B2 (en) * | 2007-04-09 | 2011-01-18 | The Board Of Trustees Of The University Of Illinois | Variably porous structures |
| US8237538B2 (en) * | 2007-04-09 | 2012-08-07 | The Board Of Trustees Of The University Of Illinois | Porous battery electrode for a rechargeable battery and method of making the electrode |
| US8426467B2 (en) * | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
| US8722736B2 (en) * | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
| US20080293814A1 (en) * | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
| US20080299391A1 (en) * | 2007-05-31 | 2008-12-04 | White Scott R | Capsules, methods for making capsules, and self-healing composites including the same |
| BRPI0815416A2 (pt) | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
| US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
| EP2055299A1 (en) * | 2007-10-23 | 2009-05-06 | Koninklijke Philips Electronics N.V. | Methods for preparing polymer microparticles |
| CN102215821B (zh) * | 2007-10-23 | 2013-05-08 | 皇家飞利浦电子股份有限公司 | 用于制备聚合物微颗粒的方法 |
| EP2222281B1 (en) | 2007-12-20 | 2018-12-05 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| EP2172264A1 (en) * | 2008-01-02 | 2010-04-07 | Ziel Biopharma Ltd | Process and apparatus for the production of microcapsules |
| US20090181254A1 (en) * | 2008-01-15 | 2009-07-16 | The Board Of Trustees Of The University Of Illinois | Multi-capsule system and its use for encapsulating active agents |
| US8115934B2 (en) | 2008-01-18 | 2012-02-14 | The Board Of Trustees Of The University Of Illinois | Device and method for imaging the ear using optical coherence tomography |
| US8983580B2 (en) | 2008-01-18 | 2015-03-17 | The Board Of Trustees Of The University Of Illinois | Low-coherence interferometry and optical coherence tomography for image-guided surgical treatment of solid tumors |
| US7751057B2 (en) | 2008-01-18 | 2010-07-06 | The Board Of Trustees Of The University Of Illinois | Magnetomotive optical coherence tomography |
| EP2085080A1 (en) * | 2008-01-30 | 2009-08-05 | LEK Pharmaceuticals D.D. | Preparation of nanoparticles by using a vibrating nozzle device |
| JP4656167B2 (ja) * | 2008-03-03 | 2011-03-23 | 株式会社日立プラントテクノロジー | 流体機器装置 |
| US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
| US20090297621A1 (en) * | 2008-06-03 | 2009-12-03 | Abbott Cardiovascular Systems Inc. | Microparticles For The Treatment Of Disease |
| US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
| WO2009158724A2 (en) | 2008-06-27 | 2009-12-30 | Tepha, Inc. | Improved injectable delivery of microparticles and compositions therefore |
| WO2010011663A2 (en) * | 2008-07-21 | 2010-01-28 | Dixie Consumer Products Llc | Paper cup manufacture with microencapsulated adhesive |
| US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
| WO2010033452A2 (en) * | 2008-09-19 | 2010-03-25 | Delaware State University Foundation, Inc. | Mono-and multi-element coded libs assays and methods |
| US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
| EA020843B1 (ru) | 2009-02-03 | 2015-02-27 | Амуникс Оперейтинг Инк. | Удлиненные рекомбинантные полипептиды и содержащие их композиции |
| EP2408372B1 (en) | 2009-03-02 | 2019-01-09 | Seventh Sense Biosystems, Inc. | Devices associated with blood sampling |
| US9041541B2 (en) | 2010-01-28 | 2015-05-26 | Seventh Sense Biosystems, Inc. | Monitoring or feedback systems and methods |
| EP2403546A2 (en) | 2009-03-02 | 2012-01-11 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
| WO2012018486A2 (en) | 2010-07-26 | 2012-02-09 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
| US9033898B2 (en) | 2010-06-23 | 2015-05-19 | Seventh Sense Biosystems, Inc. | Sampling devices and methods involving relatively little pain |
| US20120045487A1 (en) * | 2009-04-29 | 2012-02-23 | The Regents Of The University Of Michigan | Multiphasic microfibers for spatially guided cell growth |
| US20120123355A1 (en) * | 2009-07-30 | 2012-05-17 | Cook Medical Technologied | Erodible embolization material |
| US20120263701A1 (en) | 2009-08-24 | 2012-10-18 | Volker Schellenberger | Coagulation factor vii compositions and methods of making and using same |
| CA2778678A1 (en) | 2009-10-30 | 2011-05-05 | Cns Therapeutics, Inc. | Improved neurturin molecules |
| US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| JP2013514977A (ja) * | 2009-12-16 | 2013-05-02 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 複数の物質の送達のための粒子 |
| JP5432767B2 (ja) * | 2010-02-25 | 2014-03-05 | 日本光電工業株式会社 | リモートメンテナンスシステム及び中継ユニット |
| EA015780B1 (ru) * | 2010-03-11 | 2011-12-30 | Общество С Ограниченной Ответственностью "Цэм" (Ооо "Цэм") | Фармацевтическая композиция пролонгированного действия для снижения аппетита |
| US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
| JP2013531044A (ja) | 2010-07-15 | 2013-08-01 | コリンシアン オフサルミック，インコーポレイティド | 点眼薬送達 |
| US10154923B2 (en) | 2010-07-15 | 2018-12-18 | Eyenovia, Inc. | Drop generating device |
| CA2805426C (en) | 2010-07-15 | 2020-03-24 | Corinthian Ophthalmic, Inc. | Drop generating device |
| CA2805635A1 (en) | 2010-07-15 | 2012-01-19 | Corinthian Ophthalmic, Inc. | Method and system for performing remote treatment and monitoring |
| EP2593014B1 (en) | 2010-07-16 | 2015-11-04 | Seventh Sense Biosystems, Inc. | Low-pressure environment for fluid transfer devices |
| WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
| GB201016433D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Apparatus and method for making solid beads |
| GB201016436D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Method of making solid beads |
| WO2012054841A2 (en) | 2010-10-22 | 2012-04-26 | The Regents Of The University Of Michigan | Optical devices with switchable particles |
| EP2992827B1 (en) | 2010-11-09 | 2017-04-19 | Seventh Sense Biosystems, Inc. | Systems and interfaces for blood sampling |
| GB201102148D0 (en) | 2011-02-08 | 2011-03-23 | Ucl Business Plc | Layered bodies, compositions containing them and processes for producing them |
| EP2702406B1 (en) | 2011-04-29 | 2017-06-21 | Seventh Sense Biosystems, Inc. | Plasma or serum production and removal of fluids under reduced pressure |
| AU2012249692A1 (en) | 2011-04-29 | 2013-11-14 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving fluids |
| US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
| EP3106092A3 (en) | 2011-04-29 | 2017-03-08 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
| CA2859174C (en) | 2011-12-12 | 2019-03-05 | Orbis Biosciences, Inc. | Sustained release particle formulations |
| JP5960840B2 (ja) | 2011-12-12 | 2016-08-02 | アイノビア，インコーポレイティド | エジェクタ機構、エジェクタ装置及びそれらの使用方法 |
| MX369862B (es) | 2012-02-15 | 2019-11-25 | Bioverativ Therapeutics Inc | Composiciones del factor viii y metodos para hacerlas y usarlas. |
| NZ628014A (en) | 2012-02-15 | 2016-09-30 | Biogen Ma Inc | Recombinant factor viii proteins |
| US9163169B2 (en) | 2012-03-13 | 2015-10-20 | Georgia-Pacific Chemicals Llc | Adhesive compositions having a reduced cure time and methods for making and using same |
| IN2014KN02616A (enExample) | 2012-04-27 | 2015-05-08 | Georgia Pacific Chemicals Llc | |
| EP2866847B1 (en) | 2012-07-02 | 2018-08-22 | Boston Scientific Scimed, Inc. | Prosthetic heart valve formation |
| US20140294944A1 (en) | 2013-03-28 | 2014-10-02 | Kimberly-Clark Worldwide, Inc. | Microencapsulation of oxygen liberating reactants |
| SG11201508469YA (en) | 2013-05-02 | 2015-11-27 | Glaxosmithkline Ip Dev Ltd | Therapeutic peptides |
| EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
| JP6572244B2 (ja) | 2014-02-25 | 2019-09-04 | オービス バイオサイエンシズ， インク．Ｏｒｂｉｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． | 味覚マスキング薬製剤 |
| WO2015153520A1 (en) | 2014-04-02 | 2015-10-08 | Georgia-Pacific Chemicals Llc | Methods for making lignocellulose composite products with oxidative binders and encapsulated catalyst |
| CA2951905A1 (en) | 2014-06-12 | 2015-12-17 | Orbis Biosciences, Inc. | Extended-release drug delivery compositions |
| KR102125111B1 (ko) * | 2014-06-26 | 2020-06-19 | 가부시키가이샤 무라타 세이사쿠쇼 | 정극, 전지, 전지 팩, 전자 기기, 전동 차량, 축전 장치 및 전력 시스템 |
| US10149826B2 (en) | 2015-01-20 | 2018-12-11 | Hyalo Technologies, LLC | Method of preparing microspheres |
| WO2016154509A1 (en) | 2015-03-26 | 2016-09-29 | Dover Photonics Llc | Preparation of fluid samples for laser induced breakdown spectroscopy and/or imaging analysis |
| US10299915B2 (en) | 2015-04-09 | 2019-05-28 | Boston Scientific Scimed, Inc. | Synthetic heart valves composed of zwitterionic polymers |
| US10426609B2 (en) | 2015-04-09 | 2019-10-01 | Boston Scientific Scimed, Inc. | Fiber reinforced prosthetic heart valve having undulating fibers |
| US10314696B2 (en) | 2015-04-09 | 2019-06-11 | Boston Scientific Scimed, Inc. | Prosthetic heart valves having fiber reinforced leaflets |
| US10716671B2 (en) | 2015-07-02 | 2020-07-21 | Boston Scientific Scimed, Inc. | Prosthetic heart valve composed of composite fibers |
| US10413403B2 (en) | 2015-07-14 | 2019-09-17 | Boston Scientific Scimed, Inc. | Prosthetic heart valve including self-reinforced composite leaflets |
| CA2994547A1 (en) | 2015-08-03 | 2017-02-09 | Bioverativ Therapeutics Inc. | Factor ix fusion proteins and methods of making and using same |
| US10195023B2 (en) | 2015-09-15 | 2019-02-05 | Boston Scientific Scimed, Inc. | Prosthetic heart valves including pre-stressed fibers |
| US11148202B2 (en) | 2015-12-16 | 2021-10-19 | 6K Inc. | Spheroidal dehydrogenated metals and metal alloy particles |
| US10987735B2 (en) | 2015-12-16 | 2021-04-27 | 6K Inc. | Spheroidal titanium metallic powders with custom microstructures |
| GB2551944B (en) * | 2015-12-18 | 2021-09-01 | Midatech Pharma Wales Ltd | Microparticle production process and apparatus |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| EP3448360A4 (en) | 2016-04-26 | 2019-12-18 | Orbis Biosciences, Inc. | BIODEGRADABLE MICROSPHERIC COMPOSITIONS FOR PARENTERAL ADMINISTRATION |
| EP3457989B1 (en) | 2016-05-19 | 2021-09-29 | Boston Scientific Scimed, Inc. | Prosthetic valves, valve leaflets and related methods |
| US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
| JP6991165B2 (ja) * | 2016-06-23 | 2022-01-12 | シックスケー インコーポレイテッド | リチウムイオン電池材料 |
| US20180000744A1 (en) * | 2016-06-30 | 2018-01-04 | Georgia Southern Research and Service Foundation, Inc. | Nanoencapsulated compositions |
| US10654040B2 (en) | 2016-08-18 | 2020-05-19 | Northeastern University | Platform for liquid droplet formation and isolation |
| US10707531B1 (en) | 2016-09-27 | 2020-07-07 | New Dominion Enterprises Inc. | All-inorganic solvents for electrolytes |
| US10967102B2 (en) | 2016-09-28 | 2021-04-06 | Boston Scientific Limited | Cell encapsulation membranes, devices and methods |
| US11471419B2 (en) | 2016-09-30 | 2022-10-18 | The Board Of Trustees Of The University Of Illinois | Capsules with intracapsular microspheres for improved survival and function of encapsulated cells |
| TWI631985B (zh) * | 2016-10-26 | 2018-08-11 | 財團法人金屬工業研究發展中心 | 微粒製造方法 |
| WO2018102743A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| US10925998B2 (en) | 2017-04-25 | 2021-02-23 | Boston Scientific Scimed, Inc. | Method of manufacturing a biocompatible composite material |
| AU2018279940B2 (en) | 2017-06-10 | 2023-12-14 | Eyenovia, Inc. | Methods and devices for handling a fluid and delivering the fluid to the eye |
| US11173461B2 (en) | 2018-03-22 | 2021-11-16 | Lawrence Livermore National Security, Llc | Fabricating structured particles through rapid hardening and tailored collection methods |
| SG11202010767SA (en) | 2018-05-18 | 2020-11-27 | Bioverativ Therapeutics Inc | Methods of treating hemophilia a |
| WO2019246257A1 (en) | 2018-06-19 | 2019-12-26 | Amastan Technologies Inc. | Process for producing spheroidized powder from feedstock materials |
| US11684498B2 (en) | 2018-10-19 | 2023-06-27 | Inspire M.D Ltd. | Methods of using a self-adjusting stent assembly and kits including same |
| TR201818352A2 (tr) * | 2018-12-02 | 2020-06-22 | Bursa Teknik Ueniversitesi | Mi̇kroenkapsülasyon yöntemleri̇nde parti̇kül boyutunu küçülten damlatma düzeneği̇ |
| FR3089391A1 (fr) | 2018-12-05 | 2020-06-12 | V. Mane Fils | Méthode d’amelioration de l’expérience sensorielle d’un arome |
| SG11202111576QA (en) | 2019-04-30 | 2021-11-29 | 6K Inc | Mechanically alloyed powder feedstock |
| CA3134579A1 (en) | 2019-04-30 | 2020-11-05 | Gregory Wrobel | Lithium lanthanum zirconium oxide (llzo) powder |
| EP4414470A3 (en) | 2019-11-18 | 2024-10-23 | 6K Inc. | Unique feedstocks for spherical powders and methods of manufacturing |
| US12245935B2 (en) | 2019-11-26 | 2025-03-11 | Boston Scientific Limited | Composite web-polymer heart valve |
| CA3164288A1 (en) | 2019-12-11 | 2021-06-17 | Eyenovia, Inc. | Systems and devices for delivering fluids to the eye and methods of use |
| US11590568B2 (en) | 2019-12-19 | 2023-02-28 | 6K Inc. | Process for producing spheroidized powder from feedstock materials |
| CN116034496A (zh) | 2020-06-25 | 2023-04-28 | 6K有限公司 | 微观复合合金结构 |
| NL2025932B1 (en) | 2020-06-26 | 2022-02-21 | Iamfluidics Holding B V | Micro-fluidic system and method |
| US11351514B2 (en) | 2020-07-02 | 2022-06-07 | Lawrence Livermore National Security, Llc | Parallelized multiple nozzle system and method to produce layered droplets and fibers for microencapsulation |
| KR20230038183A (ko) | 2020-07-10 | 2023-03-17 | 아데어 파마슈티컬스 인코포레이티드 | 팽윤성 경구 제약 조성물 |
| WO2022067303A1 (en) | 2020-09-24 | 2022-03-31 | 6K Inc. | Systems, devices, and methods for starting plasma |
| AU2021371051A1 (en) | 2020-10-30 | 2023-03-30 | 6K Inc. | Systems and methods for synthesis of spheroidized metal powders |
| NL2027229B1 (en) * | 2020-12-24 | 2022-07-20 | Medspray B V | Device and method to aerosolize nanoparticle formulations |
| CA3197544A1 (en) | 2021-01-11 | 2022-07-14 | 6K Inc. | Methods and systems for reclamation of li-ion cathode materials using microwave plasma processing |
| US12042861B2 (en) | 2021-03-31 | 2024-07-23 | 6K Inc. | Systems and methods for additive manufacturing of metal nitride ceramics |
| US20240237689A1 (en) | 2021-05-20 | 2024-07-18 | V. Mane Fils | Flavor Beads and Method of Making and Using Same |
| WO2022246285A1 (en) * | 2021-05-21 | 2022-11-24 | The Trustees Of Columbia University In The City Of New York | Bio-microbur therapeutic delivery platform |
| GB202205123D0 (en) * | 2022-04-07 | 2022-05-25 | Univ Oxford Innovation Ltd | Encapsulation method and particle |
| US12261023B2 (en) | 2022-05-23 | 2025-03-25 | 6K Inc. | Microwave plasma apparatus and methods for processing materials using an interior liner |
| US12040162B2 (en) | 2022-06-09 | 2024-07-16 | 6K Inc. | Plasma apparatus and methods for processing feed material utilizing an upstream swirl module and composite gas flows |
| WO2024044498A1 (en) | 2022-08-25 | 2024-02-29 | 6K Inc. | Plasma apparatus and methods for processing feed material utilizing a powder ingress preventor (pip) |
| US12195338B2 (en) | 2022-12-15 | 2025-01-14 | 6K Inc. | Systems, methods, and device for pyrolysis of methane in a microwave plasma for hydrogen and structured carbon powder production |
| US12435622B2 (en) | 2023-08-22 | 2025-10-07 | Saudi Arabian Oil Company | Identifying drill cuttings with tracer pills |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US617469A (en) * | 1899-01-10 | Isaac moore | ||
| US2766064A (en) * | 1955-08-22 | 1956-10-09 | Howard V Schweitzer | Paint gun |
| US3579245A (en) * | 1967-12-07 | 1971-05-18 | Teletype Corp | Method of transferring liquid |
| IE45426B1 (en) * | 1976-07-15 | 1982-08-25 | Ici Ltd | Atomisation of liquids |
| DE2725849C3 (de) * | 1977-06-08 | 1980-11-13 | Hobeg Hochtemperaturreaktor-Brennelement Gmbh, 6450 Hanau | Vorrichtung zur Herstellung von kugelförmigen Teilchen |
| US4313403A (en) * | 1979-09-07 | 1982-02-02 | Bie Jr Norman | Internal combustion engine |
| CA1166413A (en) * | 1980-10-30 | 1984-05-01 | Edward E. Timm | Process and apparatus for preparing uniform size polymer beads |
| US4748043A (en) * | 1986-08-29 | 1988-05-31 | Minnesota Mining And Manufacturing Company | Electrospray coating process |
| EP0265924B2 (en) * | 1986-10-29 | 1998-04-22 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Uniform polymer particles |
| US4861627A (en) * | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
| US5985354A (en) * | 1995-06-07 | 1999-11-16 | Brown University Research Foundation | Preparation of multiwall polymeric microcapsules from hydrophilic polymers |
| CH675370A5 (en) | 1988-06-03 | 1990-09-28 | Ciba Geigy Ag | Filled pill mfr. - by concentric nozzles receiving ingredients from oscillating diaphragms |
| US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
| US5226948A (en) * | 1990-08-30 | 1993-07-13 | University Of Southern California | Method and apparatus for droplet stream manufacturing |
| US5260002A (en) * | 1991-12-23 | 1993-11-09 | Vanderbilt University | Method and apparatus for producing uniform polymeric spheres |
| EP0552013B1 (en) * | 1992-01-13 | 1999-04-07 | Hercules Incorporated | Thermally bondable fiber for high strength non-woven fabrics |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5711968A (en) | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5344676A (en) | 1992-10-23 | 1994-09-06 | The Board Of Trustees Of The University Of Illinois | Method and apparatus for producing nanodrops and nanoparticles and thin film deposits therefrom |
| EP1013270A3 (en) | 1992-12-02 | 2001-03-28 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
| DE4242645C2 (de) * | 1992-12-17 | 1997-12-18 | Deutsche Forsch Luft Raumfahrt | Verfahren und Einrichtung zur Herstellung von Metallkügelchen annähernd gleichen Durchmessers |
| EP2275089A1 (en) | 1993-11-19 | 2011-01-19 | Alkermes Controlled Therapeutics, Inc. | Preparation of biodegradable microparticles containing a biologically active agent |
| US5650173A (en) | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
| ES2236700T3 (es) | 1993-11-19 | 2005-07-16 | Janssen Pharmaceutica N.V. | 1,2-benzazoles microencapsulados. |
| GB9324250D0 (en) * | 1993-11-25 | 1994-01-12 | Minnesota Mining & Mfg | Inhaler |
| GB9406255D0 (en) * | 1994-03-29 | 1994-05-18 | Electrosols Ltd | Dispensing device |
| US5922253A (en) | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
| WO1997007788A2 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| AU709384B2 (en) * | 1996-03-01 | 1999-08-26 | University Of Kansas, The | Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents |
| US5792477A (en) | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
| US6196525B1 (en) | 1996-05-13 | 2001-03-06 | Universidad De Sevilla | Device and method for fluid aeration via gas forced through a liquid within an orifice of a pressure chamber |
| US6187214B1 (en) | 1996-05-13 | 2001-02-13 | Universidad De Seville | Method and device for production of components for microfabrication |
| US6197835B1 (en) * | 1996-05-13 | 2001-03-06 | Universidad De Sevilla | Device and method for creating spherical particles of uniform size |
| US6189803B1 (en) | 1996-05-13 | 2001-02-20 | University Of Seville | Fuel injection nozzle and method of use |
| ES2140998B1 (es) | 1996-05-13 | 2000-10-16 | Univ Sevilla | Procedimiento de atomizacion de liquidos. |
| US5817343A (en) | 1996-05-14 | 1998-10-06 | Alkermes, Inc. | Method for fabricating polymer-based controlled-release devices |
| US6254854B1 (en) * | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
| US5874111A (en) * | 1997-01-07 | 1999-02-23 | Maitra; Amarnath | Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles |
| US5948483A (en) | 1997-03-25 | 1999-09-07 | The Board Of Trustees Of The University Of Illinois | Method and apparatus for producing thin film and nanoparticle deposits |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US5954907A (en) * | 1997-10-07 | 1999-09-21 | Avery Dennison Corporation | Process using electrostatic spraying for coating substrates with release coating compositions, pressure sensitive adhesives, and combinations thereof |
| CA2327716A1 (en) | 1998-03-07 | 1999-09-10 | Inotech Ag | Method and device for capsulating microbial, plant and animal cells or biological and chemical substances |
| US6224794B1 (en) | 1998-05-06 | 2001-05-01 | Angiotech Pharmaceuticals, Inc. | Methods for microsphere production |
| GB2345010B (en) * | 1998-12-17 | 2002-12-31 | Electrosols Ltd | A delivery device |
| US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| BR0009993A (pt) * | 1999-04-23 | 2002-01-08 | Battelle Memorial Institute | Pulverizador de aerossol eletrohidrodinâmico direcionalmente controlado, dispositivo para liberar gotìculas de aerossol eletricamente neutras, aparelho para liberar gotìculas de aerossol terapêuticas, processo para liberar gotìculas de aerossol, e, dispositivo para liberar aerossol |
| US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| CA2419115C (en) * | 2000-08-15 | 2011-03-08 | Board Of Trustees Of The University Of Illinois | Microparticles, and method and apparatus for forming same |
| EP1404516A2 (en) * | 2000-12-13 | 2004-04-07 | Purdue Research Foundation | Microencapsulation of drugs by solvent exchange |
| US7309500B2 (en) * | 2003-12-04 | 2007-12-18 | The Board Of Trustees Of The University Of Illinois | Microparticles |
| US7748343B2 (en) * | 2004-11-22 | 2010-07-06 | The Board Of Trustees Of The University Of Illinois | Electrohydrodynamic spraying system |
-
2001
- 2001-08-15 CA CA2419115A patent/CA2419115C/en not_active Expired - Lifetime
- 2001-08-15 JP JP2002518933A patent/JP2004505761A/ja active Pending
- 2001-08-15 AT AT01964090T patent/ATE449596T1/de not_active IP Right Cessation
- 2001-08-15 EP EP01964090A patent/EP1355630B1/en not_active Expired - Lifetime
- 2001-08-15 KR KR1020087012244A patent/KR100902625B1/ko not_active Expired - Fee Related
- 2001-08-15 KR KR1020037002225A patent/KR100867392B1/ko not_active Expired - Lifetime
- 2001-08-15 WO PCT/US2001/025674 patent/WO2002013786A2/en not_active Ceased
- 2001-08-15 AU AU2001284982A patent/AU2001284982A1/en not_active Abandoned
- 2001-08-15 US US09/931,640 patent/US6669961B2/en not_active Expired - Lifetime
- 2001-08-15 DE DE60140625T patent/DE60140625D1/de not_active Expired - Lifetime
-
2003
- 2003-07-21 US US10/624,029 patent/US7368130B2/en not_active Expired - Lifetime
-
2008
- 2008-01-18 US US12/016,592 patent/US20080175915A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20030067660A (ko) | 2003-08-14 |
| US7368130B2 (en) | 2008-05-06 |
| KR20080050540A (ko) | 2008-06-05 |
| US20020054912A1 (en) | 2002-05-09 |
| US20080175915A1 (en) | 2008-07-24 |
| EP1355630B1 (en) | 2009-11-25 |
| CA2419115A1 (en) | 2002-02-21 |
| WO2002013786A2 (en) | 2002-02-21 |
| JP2004505761A (ja) | 2004-02-26 |
| DE60140625D1 (de) | 2010-01-07 |
| US20040022939A1 (en) | 2004-02-05 |
| EP1355630A2 (en) | 2003-10-29 |
| KR100867392B1 (ko) | 2008-11-06 |
| AU2001284982A1 (en) | 2002-02-25 |
| ATE449596T1 (de) | 2009-12-15 |
| KR100902625B1 (ko) | 2009-06-15 |
| WO2002013786A3 (en) | 2003-08-28 |
| US6669961B2 (en) | 2003-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2419115C (en) | Microparticles, and method and apparatus for forming same | |
| US8409621B2 (en) | Microparticles | |
| Berkland et al. | Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions | |
| Chong et al. | Advances in fabricating double-emulsion droplets and their biomedical applications | |
| Tran et al. | Why and how to prepare biodegradable, monodispersed, polymeric microparticles in the field of pharmacy? | |
| Bahrami et al. | Production of micro-and nano-composite particles by supercritical carbon dioxide | |
| Freitas et al. | Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology | |
| CN101410174B (zh) | 一种用于生产基于乳化的微观粒子的方法 | |
| SE512663C2 (sv) | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer | |
| TWI643680B (zh) | 微粒噴頭 | |
| Padalkar et al. | Microparticles: an approach for betterment of drug delivery system | |
| WO2005061095A9 (ja) | 微小球体の製造方法およびその製造装置 | |
| Liu et al. | Tailoring particle microstructures via supercritical CO2 processes for particular drug delivery | |
| JP2004035446A (ja) | 微小球体の製造方法およびその製造装置 | |
| JP2004262810A (ja) | 薬物含有複合粒子の製造方法および経肺製剤 | |
| CN107573523B (zh) | 一种偏心结构聚合物微球及其制备方法 | |
| Athar Alli | Dry-Coating of Powder Particles is Current Trend in Pharmaceutical Field. | |
| Kumar et al. | Microparticles for cancer therapy | |
| TWI660789B (zh) | 微粒成形裝置及其微粒成形方法 | |
| Berkland | Control of micro-and nano-sphere size distributions: Implications in drug delivery | |
| Song et al. | Application of nanofluids to microsphere generation using MEMS technology | |
| Sacchetin et al. | Advances in the use of supercritical fluids for the production of poly (α-hydroxyester) particles incorporating bioactive agents | |
| Yadav et al. | 47 Microparticulate Drug Delivery Systems | |
| Cui et al. | Towards monodisperse microbubble populations via microfluidic chip flow-focusing | |
| Xia | Uniform double wall microspheres/microcapsules for protein delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20210816 |
|
| MKEX | Expiry |
Effective date: 20210816 |